5 Key Takeaways

• 1

  Professor Eric Souied has joined SeaBeLife's scientific committee to advance its dual-pathway strategy targeting retinal degeneration.

• 2

  Souied will guide the company's ophthalmology program, focusing on inhibiting necroptosis and ferroptosis in retinal diseases.

• 3

  SeaBeLife claims its platform uniquely addresses both necroptosis and ferroptosis mechanisms in tandem.

• 4

  Souied has authored over 650 publications and identified the first genetic polymorphism linked to age-related macular degeneration.

• 5

  SeaBeLife's lead candidate, SBL03, shows preclinical efficacy in geographic atrophy, affecting an estimated eight million people globally.